Related Experiment Videos
Degradation and oxidation of methionine enkephalin by human neutrophils
Abstract:
Met5-enkephalin, tyr-gly-phe-met, is an endogenous pentapeptide, with morphine agonist activity. In this study, we demonstrated that met5-enkephalin was degraded with the release of tyrosine by resting human PMN, whereas it was degraded as well as oxidized to its sulfoxide derivative, met5-(O)-enkephalin, by phagocytosing PMN. PMN also degraded met5-(O)-enkephalin but to a lesser extent. Bacitracin at 1 gm/L inhibited the degradation and oxidation of met5-enkephalin without affecting the production of superoxide and viability of PMN. The oxidation of met5-enkephalin by phagocytosing PMN was inhibited by catalase or NaN3 but not by SOD. This suggests that the oxidation of met5-enkephalin by phagocytosing PMN was, at least in part, dependent on the MPO system (MPO-H2O2-halide). Using purified canine MPO, we further demonstrated that MPO-H2O2-CI- oxidized met5-enkephalin to met5-(O)-enkephalin. The MPO-mediated oxidation of met5-enkephalin was inhibited by methionine but not by methionine sulfoxide, tyrosine, glycine, or phenylalanine, confirming that it was the methionine moiety of met5-enkephalin which was oxidized. Since both the sulfoxide derivative and the degradation products met5-enkephalin have reduced opiate agonist activity, oxidation and degradation of met5-enkephalin by PMN may contribute to the pain at the site of inflammation. (J Lab Clin Med 99:418, 1982.)
Insights
Human neutrophils (PMN) degrade and oxidize met5-enkephalin, a pain-related peptide. This process, mediated by the myeloperoxidase (MPO) system, reduces its opiate activity and may contribute to inflammation-induced pain.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Met5-enkephalin is an endogenous pentapeptide with morphine agonist activity.
- Human neutrophils (PMN) play a role in inflammatory processes.
Purpose of the Study:
- To investigate the degradation and oxidation of met5-enkephalin by human PMN.
- To elucidate the mechanisms involved in met5-enkephalin modification by PMN.
Main Methods:
- Incubation of met5-enkephalin with resting and phagocytosing human PMN.
- Analysis of met5-enkephalin degradation and oxidation products.
- Enzymatic assays using purified myeloperoxidase (MPO) and inhibitors.
Main Results:
- Resting PMN degraded met5-enkephalin, releasing tyrosine.
- Phagocytosing PMN degraded and oxidized met5-enkephalin to met5-(O)-enkephalin.
- MPO-H2O2-halide system was responsible for met5-enkephalin oxidation, targeting the methionine residue.
- Bacitracin inhibited degradation and oxidation, while catalase or NaN3 inhibited oxidation.
Conclusions:
- PMN degrade and oxidize met5-enkephalin, reducing its opiate agonist activity.
- The MPO system is involved in the oxidation of met5-enkephalin by phagocytosing PMN.
- These modifications may contribute to pain signaling at inflammatory sites.